Abstract Number: 619 • 2013 ACR/ARHP Annual Meeting
Survival and Prognostic Factors In Patients With Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Results From Korean Nationwide Registry
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissue disease (CTD). We sought to quantify survival and determine factors predictive…Abstract Number: 620 • 2013 ACR/ARHP Annual Meeting
Human Papillomavirus and Precancerous Lesions In Patients With Systemic Lupus Erythematosus
Background/Purpose: To evaluate the presence of Precancerous Lesions (PL) in uterine cervix in patients with Systemic Lupus Erythematosus (SLE) and its relationship with Human Papillomavirus…Abstract Number: 621 • 2013 ACR/ARHP Annual Meeting
Baseline Characteristics That Predict a Short-Term Response To Immunosuppressive Treatment In Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of devastating organ involvements in patients with connective tissue diseases (CTDs). Recent introduction of molecular-targeting PAH drugs, such…Abstract Number: 591 • 2013 ACR/ARHP Annual Meeting
Elevated Level Of cfDNA Mainly Derive From Netosis Of Common Neutrophils As Well As Low-Density Granulocytes In Systemic Lupus Erythematosus and Is Associated With Lupus Nephritis Severity
Background/Purpose: Insufficient clearance of neutrophil extracellular traps (NETs) has been involved in lupus nephritis and can cause the increase of residual NETs in vivo, which…Abstract Number: 598 • 2013 ACR/ARHP Annual Meeting
Gender Influence On Lupus Nephritis Outcomes In An Urban, Multiethnic Population
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease predominately of young women that disproportionately affects minorities. Lupus Nephritis (LN) causes major morbidity and mortality in…Abstract Number: 582 • 2013 ACR/ARHP Annual Meeting
A Real-World Survey Of Clinical Practice Among Rheumatologists and Nephrologists In The United States Reveals Differences In Care Of Non-Nephritis Systemic Lupus Erythematosus and Lupus Nephritis As Compared With American College Of Rheumatology Treatment Guidelines
Background/Purpose: Current pharmacotherapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN) includes combinations of nonsteroidal anti–inflammatory drugs (NSAIDs), antimalarials (AMs), glucocorticoids (GCs), and cytotoxic…Abstract Number: 583 • 2013 ACR/ARHP Annual Meeting
Prognostic Significance Of Visit-To-Visit Variability, Maximum Systolic Blood Pressure, and Episodic Hypertension In Sytemic Lupus Erythematosus
Background/Purpose: SLE is considered a coronary heart disease equivalent and aggressive management of all traditional risk factors is recommended. Hypertension is a major problem in…Abstract Number: 584 • 2013 ACR/ARHP Annual Meeting
The Effect Of Ramipril On Endothelial Function and Endothelial Progenitor Cells In Patients With Systemic Lupus Erythematosus
Background/Purpose: Cardiovascular diseases (CVD) are one of major causes of morbidity and mortality in SLE patients. Traditional cardiovascular risk factors and disease intrinsic factors contribute…Abstract Number: 585 • 2013 ACR/ARHP Annual Meeting
Breast Cancer In Systemic Lupus (SLE): Do Demographic and Clinical Factors, Including DNA serology, Influence Risk?
Background/Purpose: There is an increase in cancer in SLE over-all, but decrease in other cancers, such as breast cancer. Of particular interest are autoantibodies targeting…Abstract Number: 586 • 2013 ACR/ARHP Annual Meeting
Blood Pressure Variability and Age-Related Blood Pressure Patterns In Systemic Lupus Erythematosus
Background/Purpose: Increased visit-to-visit blood pressure (BP) variability has been associated with an increased risk of all-cause mortality, stroke, left ventricular diastolic dysfunction, and cognitive impairment…Abstract Number: 587 • 2013 ACR/ARHP Annual Meeting
Low-Dose Aspirin Has An Anti-Platelet Effect In Systemic Lupus Erythematosus
Background/Purpose: Thrombosis is increased in SLE patients, with and without antiphospholipid antibodies. Aspirin and hydroxychloroquine are thought to have anti-platelet effects. We determined whether these…Abstract Number: 588 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Rituximab In Patients With Refractory Lupus Nephritis, a Post-Hoc Analysis From Phase II Trial In Japan
Background/Purpose: B-cell depletion therapy by rituximab has been reported to be useful for treatment of lupus nephritis (LN) in many observational uncontrolled studies, however, placebo-controlled…Abstract Number: 589 • 2013 ACR/ARHP Annual Meeting
A Survey Of Physician and Patient Satisfaction With Control Of Systemic Lupus Erythematosus and Lupus Nephritis
Background/Purpose: Patient satisfaction with disease control is an important component of overall health and well-being. Current treatment options for systemic lupus erythematosus (SLE) ±lupus nephritis…Abstract Number: 590 • 2013 ACR/ARHP Annual Meeting
Candidate Urinary Biomarkers May Predict The Future Development Of Renal Functional Loss With Lupus Nephritis In Children and Adults
Background/Purpose: Lupus nephritis(LN) is frequently associated with a poor long-term prognosis. Current non-invasive blood and urine tests do not reliably predict the course of LN.…Abstract Number: 592 • 2013 ACR/ARHP Annual Meeting
Analysis Of Relationship Between Clinical Manifestations and Autoantibody Profile In ISN/RPS Class V Lupus Nephritis
Background/Purpose: Clinical manifestations, pathohistology and treatment strategy are different between International Society of Nephrology/Renal Pathology Society (ISN /RPS) class III/IV and class V Lupus Nephritis…